Schroders PLC/ GB00BP9LHF23 /
2024-11-19 5:28:41 PM | Chg. -3.30 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
310.60GBX | -1.05% | 304,698 Turnover(GBP): 939,950.4010 |
-Bid Size: - | -Ask Size: - | 4.91 mill.GBP | - | - |
GlobeNewswire
04-10
Questex’s IHIF EMEA 2024: The Meeting Place of Hospitality Innovators and Game-Changers
GlobeNewswire
04-02
New York UNCF 80th Anniversary “A Mind Is…”® Gala Raises Nearly $950,000 for HBCUs and Students
GlobeNewswire
03-12
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat i...
GlobeNewswire
02-08
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Ca...
GlobeNewswire
01-23
Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th a...
GlobeNewswire
2023-12-11
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enr...
GlobeNewswire
2023-09-13
Investcorp-Tages Partnering with Engadine to Broaden its Single Strategy Offerings with the Engadine...
GlobeNewswire
2022-03-09
iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR
GlobeNewswire
2021-12-09
iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3Kδ Inhibitor ...
GlobeNewswire
2021-12-09
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autot...
GlobeNewswire
2021-11-23
iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December